
    
      The purpose of this study is to establish the safety profile and maximum tolerated dose (MTD)
      of the anti-PDGFRÎ± monoclonal antibody IMC-3G3 in patients with advanced solid tumors who no
      longer respond to standard therapy or for whom no standard therapy is available.
    
  